169 related articles for article (PubMed ID: 18325065)
21. From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol.
Colvin LA; Johnson PR; Mitchell R; Fleetwood-Walker SM; Fallon M
J Clin Oncol; 2008 Sep; 26(27):4519-20. PubMed ID: 18802169
[No Abstract] [Full Text] [Related]
22. Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment.
Giaccone L; Sorasio R; Patriarca F; Mattei D; Montefusco V; Peccatori J; Carnevale-Schianca F; Petrucci MT; Milone G; Guidi S; Rotta M; Fanin R; Corradini P; Boccadoro M; Bruno B
Biol Blood Marrow Transplant; 2007 Apr; 13(4):497-9. PubMed ID: 17382258
[No Abstract] [Full Text] [Related]
23. [Bortezomib-induced eruption: Sweet syndrome? Two case reports].
Thuillier D; Lenglet A; Chaby G; Royer R; Vaida I; Viseux V; Dadban A; Billet A; Christophe O; Chatelain D; Marolleau JP; Lok C; Damaj G
Ann Dermatol Venereol; 2009 May; 136(5):427-30. PubMed ID: 19442799
[TBL] [Abstract][Full Text] [Related]
24. Sweet-like lesions induced by bortezomib: a review of the literature and a report of 2 cases.
Truchuelo M; Bagazgoitia L; Alcántara J; Velasco D; Carrillo R
Actas Dermosifiliogr; 2012 Nov; 103(9):829-31. PubMed ID: 22652505
[No Abstract] [Full Text] [Related]
25. Bortezomib-associated rash: a new recognizable and avoidable side-effect.
Villarrubia B; Betlloch I; Mataix J; Lucas A; Botella C
Br J Dermatol; 2007 Apr; 156(4):784-5. PubMed ID: 17286633
[No Abstract] [Full Text] [Related]
26. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
[TBL] [Abstract][Full Text] [Related]
27. [Cisplatin induced reversible posterior leukoencephalopathy].
Díaz Díaz J; Germán Díaz M; Barrios López M; Martinez De Aragón A; Simón De Las Heras R; Camacho Salas A
An Pediatr (Barc); 2012 Oct; 77(4):281-2. PubMed ID: 22459609
[No Abstract] [Full Text] [Related]
28. Bortezomib-induced histiocytoid Sweet syndrome.
Murase JE; Wu JJ; Theate I; Cole GW; Barr RJ; Dyson SW
J Am Acad Dermatol; 2009 Mar; 60(3):496-7. PubMed ID: 19231647
[TBL] [Abstract][Full Text] [Related]
29. [Aggravated post-herpetic neuralgia due to bortezomib].
Kirizume K; Imataki O; Shintani T; Fujihara S; Waki F; Ohue Y; Ohnishi H
Rinsho Ketsueki; 2008 May; 49(5):331-4. PubMed ID: 18572810
[TBL] [Abstract][Full Text] [Related]
30. Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs.
Marinella MA; Markert RJ
Intern Med J; 2009 Dec; 39(12):826-34. PubMed ID: 19220526
[TBL] [Abstract][Full Text] [Related]
31. Immune-mediated neuropathies in myeloma patients treated with bortezomib.
Ravaglia S; Corso A; Piccolo G; Lozza A; Alfonsi E; Mangiacavalli S; Varettoni M; Zappasodi P; Moglia A; Lazzarino M; Costa A
Clin Neurophysiol; 2008 Nov; 119(11):2507-12. PubMed ID: 18829381
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib: 3 deaths following intrathecal injection.
Prescrire Int; 2012 Sep; 21(130):214. PubMed ID: 23016258
[No Abstract] [Full Text] [Related]
33. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
Lanzani F; Mattavelli L; Frigeni B; Rossini F; Cammarota S; Petrò D; Jann S; Cavaletti G
J Peripher Nerv Syst; 2008 Dec; 13(4):267-74. PubMed ID: 19192066
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy-induced neuropathic pain.
Farquhar-Smith P
Curr Opin Support Palliat Care; 2011 Mar; 5(1):1-7. PubMed ID: 21192267
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib-induced peripheral neuropathy: facts and genes.
Cavaletti G
Lancet Oncol; 2011 Feb; 12(2):120-1; author reply 121. PubMed ID: 21277549
[No Abstract] [Full Text] [Related]
36. Bortezomib-induced neurogenic bladder in patients with multiple myeloma.
Shimura K; Shimazaki C; Taniguchi K; Inaba T; Horiike S; Taniwaki M
Ann Hematol; 2009 Apr; 88(4):383-4. PubMed ID: 18836719
[No Abstract] [Full Text] [Related]
37. Cooperative relationship between pharmaceutical companies, academia, and media explains sharp decrease in frequency of pulmonary complications after bortezomib in Japan.
Narimatsu H; Hori A; Matsumura T; Kodama Y; Takita M; Kishi Y; Hamaki T; Yuji K; Tanaka Y; Komatsu T; Kami M
J Clin Oncol; 2008 Dec; 26(35):5820-3. PubMed ID: 19001340
[No Abstract] [Full Text] [Related]
38. [Pulmonary toxicity after bortezomib].
Cañete C; Soley A; Vuelta Arce M; Escoda L
Farm Hosp; 2008; 32(5):301-2. PubMed ID: 19150049
[No Abstract] [Full Text] [Related]
39. Chemotherapy-induced reversible posterior leucoencephalopathy syndrome.
Han CH; Findlay MP
Intern Med J; 2010 Feb; 40(2):153-9. PubMed ID: 20446957
[TBL] [Abstract][Full Text] [Related]
40. Nonconvulsive status epilepticus related to posterior reversible leukoencephalopathy syndrome induced by cetuximab.
Palma JA; Gomez-Ibañez A; Martin B; Urrestarazu E; Gil-Bazo I; Pastor MA
Neurologist; 2011 Sep; 17(5):273-5. PubMed ID: 21881470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
